PAINT-2DTM platform is our proprietary platform equipped with “one-stop” functionalities for the early-stage development of immuno-oncology therapies, and enables us to study the functions of immuno-oncology therapies and their effects on immune cells in an efficient manner, as well as to evaluate the combination potential of different immuno-oncology therapies and the toxicity and adverse events for different combination regimens.
By utilizing immune cell lines, primary immune cells, ex vivo tumor/tumor-infiltrating lymphocyte (TIL), PAINT-2DTM platform is able to perform a series of assays to comprehensively assess (i) the effects of immuno-oncology drugs on the functioning of immune cells, including T-cells, B-cells, DCs, monocytes, and macrophages, and (ii) the combination potentials and off-target effects for different immuno-oncology drugs. This allows us to (i) thoroughly optimize the efficacy and undesired adverse events of drug candidates to maximize their efficacy in immuno-oncology, and (ii) fully assess the combinatorial synergies between different drugs in preclinical stages, and (iii) potentially correlate preclinical output with clinical performance using data generated internally. This platform is expected to lead to optimal candidate molecules and combination regimens to potentially reduce the risks associated with subsequent clinical trials.
Our ANEAT-Id technology is a highly efficient and robust yeast display system that is dedicated to therapeutic antibody discovery and development. It features 1) a super-size human antibody library; 2) high display efficiency; 3) a display/secretion switchable design; and 4) various developability assessment tools. Adlai Nortye is utilizing ANEAT-Id technology to facilitate and accelerate therapeutic antibody R&D.